Compare DexCom, Inc. (DXCM) vs Nasdaq100 ETF (QQQ) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

QQQ trades at $709.87, down 1.36% today amid neutral technical signals. The ETF shows mixed analyst sentiment with a 50/50 buy/sell split among covered analysts. Recent news highlights competitive dynamics with lower-fee alternatives like QQQM and the impact of SpaceX's addition to the Nasdaq-100 index. Technical indicators show the stock trading near key support at $711 with overall neutral momentum.

The outlook remains balanced with exposure to leading tech growth companies but faces headwinds from fee competition and index concentration risks. Upside potential exists through continued AI-driven growth, while downside risks include market volatility and ETF fee pressure. The neutral technical setup suggests near-term consolidation is likely.